ReviewViruses2022
Immune-Mediated Pathogenesis in Dengue Virus Infection.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 102 citations in OpenAlex.
- Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.The Journal of infectious diseases · 2025Trial
- The Impact of Antigen Presentation on BBB Disruption and Neuroinflammation.Physiology (Bethesda, Md.) · 2026Review
- Molecular characterization and recent spread of dengue virus type 3 lineage III_B.3.2 in Brazil: in silico analysis of protein motifs and epidemiology.Virus genes · 2026Article
- Rethinking Clinical Trial Design to Accelerate Therapeutics for Arboviral Epidemics.Open forum infectious diseases · 2026Article
- Pathogenesis and neurotropism of a contemporary Powassan virus lineage II strain in mice.Journal of virology · 2026Article
- Severe Dengue in Children: Pathogenesis, Early Recognition, and Evidence-Informed Management.Tropical medicine and infectious disease · 2026Review
- Bulk transcriptomics of peripheral blood mononuclear cells delineates systems-level immune dysregulation in pediatric dengue infection.NPJ systems biology and applications · 2026Article
- The Role of Natural Killer (NK) Cells in Dengue Virus Infection: A Narrative Review.Health science reports · 2026Article
- Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Discovery of 10-Shogaol fromJournal of agricultural and food chemistry · 2026Article
- Decoding Thrombocytopenia in Dengue: Platelet Indices Define Mechanistic Phenotypes and Predict Bleeding Risk.Cureus · 2026Article
- Dynamic landscape of peripheral blood lymphocyte subsets in dengue patients: a multimodal single-cell and flow cytometry analysis.BMC infectious diseases · 2026Article
- Metabolomic atlas of dengue virus infection reveals distinct circulating bioactive lipid signatures.PLoS neglected tropical diseases · 2026Article
- The Second Silent Pandemic: Why Arboviruses Demand an Orchestrated Global Health Response.Pathogens (Basel, Switzerland) · 2026Review
- Dengue Virus-Susceptible Animal Models: Research Progress, Core Bottlenecks, and Future Perspectives.Vaccines · 2026Review
- Purinergic signaling in dengue infection: modulation of P2 receptors as a potential therapeutic strategy.Purinergic signalling · 2026Review
- Transplant-free survival in dengue-associated acute liver failure: Current evidence and future directions.World journal of virology · 2026Review
- A Large Dengue Outbreak in Taiwan, 2023: Driven by Imported Cases, Serotype Cocirculation, and Climate Variability.Open forum infectious diseases · 2026Article
- Protective Role of Vitamins C, D, and K in the Management of Dengue: A Narrative Review to Combat the Dengue Outbreak.Health science reports · 2026Article
- A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy.The Journal of infectious diseases · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV) infection is one of the major public health concerns around the globe, especially in the tropical regions of the world that contribute to 75% percent of dengue cases. While the majority of DENV infections are mild or asymptomatic, approximately 5% of the cases develop a severe form of the disease that is mainly attributed to sequential infection with different DENV serotypes. The severity of dengue depends on many immunopathogenic mechanisms involving both viral and host factors. Emerging evidence implicates an impaired immune response as contributing to disease progression and severity by restricting viral clearance and inducing severe inflammation, subsequently leading to dengue hemorrhagic fever and dengue shock syndrome. Moreover, the ability of DENV to infect a wide variety of immune cells, including monocytes, macrophages, dendritic cells, mast cells, and T and B cells, further dysregulates the antiviral functions of these cells, resulting in viral dissemination. Although several risk factors associated with disease progression have been proposed, gaps persist in the understanding of the disease pathogenesis and further investigations are warranted. In this review, we discuss known mechanisms of DENV-mediated immunopathogenesis and its association with disease progression and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.